146 related articles for article (PubMed ID: 9042371)
21. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum.
Grauer LS; Finlay JA; Mikolajczyk SD; Pusateri KD; Wolfert RL
J Androl; 1998; 19(4):407-11. PubMed ID: 9733142
[TBL] [Abstract][Full Text] [Related]
22. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.
Lövgren J; Rajakoski K; Karp M; Lundwall â ; Lilja H
Biochem Biophys Res Commun; 1997 Sep; 238(2):549-55. PubMed ID: 9299549
[TBL] [Abstract][Full Text] [Related]
23. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids.
Yousef GM; Kapadia C; Polymeris ME; Borgono C; Hutchinson S; Wasney GA; Soosaipillai A; Diamandis EP
Biochim Biophys Acta; 2003 Jul; 1628(2):88-96. PubMed ID: 12890555
[TBL] [Abstract][Full Text] [Related]
24. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling.
Bridon DP; Dowell BL
Urology; 1995 May; 45(5):801-6. PubMed ID: 7538242
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of tissue kallikrein by protein C inhibitor. Evidence for identity of protein C inhibitor with the kallikrein binding protein.
Ecke S; Geiger M; Resch I; Jerabek I; Sting L; Maier M; Binder BR
J Biol Chem; 1992 Apr; 267(10):7048-52. PubMed ID: 1313031
[TBL] [Abstract][Full Text] [Related]
26. Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.
Harpel PC
J Exp Med; 1970 Aug; 132(2):329-52. PubMed ID: 4101346
[TBL] [Abstract][Full Text] [Related]
27. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2.
Kumar A; Mikolajczyk SD; Goel AS; Millar LS; Saedi MS
Cancer Res; 1997 Aug; 57(15):3111-4. PubMed ID: 9242434
[TBL] [Abstract][Full Text] [Related]
28. [Purification and some physico-chemical and enzymatic properties of tissue kallikrein from human urine].
Rabinovich SE; Lobareva LS; Paskhina TS
Biokhimiia; 1990 Sep; 55(9):1675-89. PubMed ID: 2078641
[TBL] [Abstract][Full Text] [Related]
29. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.
Denmeade SR; Lövgren J; Khan SR; Lilja H; Isaacs JT
Prostate; 2001 Jul; 48(2):122-6. PubMed ID: 11433422
[TBL] [Abstract][Full Text] [Related]
30. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue.
Mikolajczyk SD; Millar LS; Marker KM; Rittenhouse HG; Wolfert RL; Marks LS; Charlesworth MC; Tindall DJ
Cancer Res; 1999 Aug; 59(16):3927-30. PubMed ID: 10463585
[TBL] [Abstract][Full Text] [Related]
31. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence.
Zhou GX; Chao L; Chao J
J Biol Chem; 1992 Dec; 267(36):25873-80. PubMed ID: 1334488
[TBL] [Abstract][Full Text] [Related]
32. Isolation of an enzymatically active tissue kallikrein from human seminal plasma by immunoaffinity chromatography.
Geiger R; Clausnitzer B
Hoppe Seylers Z Physiol Chem; 1981 Sep; 362(9):1279-83. PubMed ID: 6921144
[TBL] [Abstract][Full Text] [Related]
33. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
34. Biological activity of prostate-specific antigen isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroelution.
Tessmer U; Quack T; Donn F; Leuner A; Dernick R
Electrophoresis; 1995 May; 16(5):793-9. PubMed ID: 7588564
[TBL] [Abstract][Full Text] [Related]
35. Complex formation between human kallikrein 13 and serum protease inhibitors.
Kapadia C; Yousef GM; Mellati AA; Magklara A; Wasney GA; Diamandis EP
Clin Chim Acta; 2004 Jan; 339(1-2):157-67. PubMed ID: 14687906
[TBL] [Abstract][Full Text] [Related]
36. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator.
Frenette G; Tremblay RR; Lazure C; Dube JY
Int J Cancer; 1997 May; 71(5):897-9. PubMed ID: 9180162
[TBL] [Abstract][Full Text] [Related]
37. Identification of human glandular kallikrein hK2 from LNCaP cells.
Grauer LS; Charlesworth MC; Saedi MS; Finlay JA; Liu RS; Kuus-Reichel K; Young CY; Tindall DJ
J Androl; 1996; 17(4):353-9. PubMed ID: 8889697
[TBL] [Abstract][Full Text] [Related]
38. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells.
Väisänen V; Lövgren J; Hellman J; Piironen T; Lilja H; Pettersson K
Prostate Cancer Prostatic Dis; 1999 Mar; 2(2):91-97. PubMed ID: 12496845
[TBL] [Abstract][Full Text] [Related]
39. Development of plasma kallikrein selective inhibitors.
Okada Y; Tsuda Y; Tada M; Wanaka K; Hijikata-Okunomiya A; Okamoto U; Okamoto S
Biopolymers; 1999; 51(1):41-50. PubMed ID: 10380351
[TBL] [Abstract][Full Text] [Related]
40. Complexes of tissue kallikrein with protein C inhibitor in human semen and urine.
España F; Fink E; Sanchez-Cuenca J; Gilabert J; Estellés A; Witzgall K
Eur J Biochem; 1995 Dec; 234(2):641-9. PubMed ID: 8536714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
